RB1 and small cell lung carcinoma: Preliminary data indicate that RB1 wild-type tumors may have better outcomes when receiving NSCLC-type chemotherapy (platinum–gemcitabine or paclitaxel) than platinum–etoposide SCLC-like chemotherapy [118].